Literature DB >> 29030102

Lolium perenne peptides for treatment of grass pollen allergy: A randomized, double-blind, placebo-controlled clinical trial.

Mohamed H Shamji1, Jan Ceuppens2, Claus Bachert3, Peter Hellings4, Gaël Placier5, Gaëtan Thirion5, Nicolas Bovy5, Stephen R Durham6, Jean Duchateau5, Thierry Legon5, Sabine Pirotton5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29030102     DOI： 10.1016/j.jaci.2017.09.013

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  5 in total

1.  Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double-blind, placebo-controlled trial.

Authors:  R Mösges; C Bachert; P Panzner; M A Calderon; L Haazen; S Pirotton; N Wathelet; S R Durham; M-A Bonny; T Legon; R von Frenckell; O Pfaar; M H Shamji
Journal:  Allergy       Date:  2018-06-21       Impact factor: 13.146

2.  Lolium perenne peptide immunotherapy is well tolerated and elicits a protective B-cell response in seasonal allergic rhinitis patients.

Authors:  R Mösges; A F Koch; E Raskopf; J Singh; K Shah-Hosseini; A Astvatsatourov; B Hauswald; Y Yarin; F Corazza; L Haazen; S Pirotton; S Allekotte; G Zadoyan; T Legon; S R Durham; M H Shamji
Journal:  Allergy       Date:  2018-02-13       Impact factor: 13.146

Review 3.  Towards definitive management of allergic rhinitis: best use of new and established therapies.

Authors:  Lubnaa Hossenbaccus; Sophia Linton; Sarah Garvey; Anne K Ellis
Journal:  Allergy Asthma Clin Immunol       Date:  2020-05-27       Impact factor: 3.406

4.  A randomized, double-blind, placebo-controlled, dose-finding trial with Lolium perenne peptide immunotherapy.

Authors:  R Mösges; E M Kasche; E Raskopf; J Singh; L Sohlich; A Astvatsatourov; K Shah-Hosseini; S Pirotton; L Haazen; S R Durham; T Legon; G Zadoyan; M H Shamji
Journal:  Allergy       Date:  2017-12-22       Impact factor: 13.146

Review 5.  Allergen-Specific Antibodies Regulate Secondary Allergen-Specific Immune Responses.

Authors:  Julia Eckl-Dorna; Sergio Villazala-Merino; Birgit Linhart; Alexander V Karaulov; Yury Zhernov; Musa Khaitov; Verena Niederberger-Leppin; Rudolf Valenta
Journal:  Front Immunol       Date:  2019-01-17       Impact factor: 7.561
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.